ALLO – Allogene Therapeutics, Inc.
Float Short %
11.28
Margin Of Safety %
Put/Call OI Ratio
0.11
EPS Next Q Diff
-0.02
EPS Last/This Y
0.38
EPS This/Next Y
0.05
Price
1.72
Target Price
7.38
Analyst Recom
1.47
Performance Q
36.51
Relative Volume
1.95
Beta
0.59
Ticker: ALLO
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-12-26 | ALLO | 1.385 | 0.10 | 0.00 | 3661 |
| 2025-12-29 | ALLO | 1.38 | 0.11 | 0.00 | 3650 |
| 2025-12-30 | ALLO | 1.305 | 0.11 | 0.00 | 3629 |
| 2025-12-31 | ALLO | 1.37 | 0.09 | 0.00 | 4281 |
| 2026-01-02 | ALLO | 1.355 | 0.09 | 0.01 | 4299 |
| 2026-01-05 | ALLO | 1.355 | 0.09 | 0.00 | 4391 |
| 2026-01-06 | ALLO | 1.405 | 0.09 | 0.00 | 4414 |
| 2026-01-07 | ALLO | 1.49 | 0.08 | 0.29 | 4935 |
| 2026-01-08 | ALLO | 1.49 | 0.08 | 0.52 | 5045 |
| 2026-01-09 | ALLO | 1.71 | 0.09 | 0.08 | 5104 |
| 2026-01-12 | ALLO | 1.67 | 0.07 | 0.07 | 5817 |
| 2026-01-13 | ALLO | 1.63 | 0.07 | 0.02 | 6010 |
| 2026-01-14 | ALLO | 1.7 | 0.07 | 0.99 | 6386 |
| 2026-01-15 | ALLO | 1.62 | 0.09 | 20.17 | 6618 |
| 2026-01-16 | ALLO | 1.63 | 1.27 | 0.14 | 14053 |
| 2026-01-20 | ALLO | 1.575 | 0.08 | 0.24 | 5417 |
| 2026-01-21 | ALLO | 1.595 | 0.09 | 2.31 | 5646 |
| 2026-01-22 | ALLO | 1.725 | 0.11 | 0.55 | 5786 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-12-26 | ALLO | 1.38 | 20.3 | - | -0.94 |
| 2025-12-29 | ALLO | 1.38 | 20.3 | - | -0.94 |
| 2025-12-30 | ALLO | 1.30 | 20.3 | - | -0.94 |
| 2025-12-31 | ALLO | 1.37 | 20.3 | - | -0.94 |
| 2026-01-02 | ALLO | 1.36 | 20.3 | - | -0.94 |
| 2026-01-05 | ALLO | 1.35 | 20.3 | - | -0.94 |
| 2026-01-06 | ALLO | 1.40 | 20.3 | - | -0.94 |
| 2026-01-07 | ALLO | 1.50 | 20.3 | - | -0.94 |
| 2026-01-08 | ALLO | 1.50 | 20.3 | - | -0.94 |
| 2026-01-09 | ALLO | 1.70 | 20.3 | - | -0.94 |
| 2026-01-12 | ALLO | 1.66 | 19.9 | - | -0.94 |
| 2026-01-13 | ALLO | 1.63 | 19.9 | - | -0.94 |
| 2026-01-14 | ALLO | 1.70 | 19.9 | - | -0.94 |
| 2026-01-15 | ALLO | 1.62 | 19.9 | - | -0.94 |
| 2026-01-16 | ALLO | 1.63 | 21.7 | - | -0.94 |
| 2026-01-20 | ALLO | 1.58 | 21.7 | - | -0.94 |
| 2026-01-21 | ALLO | 1.60 | 21.7 | - | -0.94 |
| 2026-01-22 | ALLO | 1.72 | 21.7 | - | -0.94 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-12-26 | ALLO | -0.06 | -9.57 | 11.26 |
| 2025-12-29 | ALLO | -0.06 | -9.58 | 11.26 |
| 2025-12-30 | ALLO | -0.06 | -9.58 | 11.26 |
| 2025-12-31 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-02 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-05 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-06 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-07 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-08 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-09 | ALLO | -0.06 | -9.58 | 11.26 |
| 2026-01-12 | ALLO | -0.07 | -9.60 | 11.26 |
| 2026-01-13 | ALLO | -0.06 | -9.60 | 11.28 |
| 2026-01-14 | ALLO | -0.06 | -9.60 | 11.28 |
| 2026-01-15 | ALLO | -0.06 | -9.60 | 11.28 |
| 2026-01-16 | ALLO | -0.06 | -9.60 | 11.28 |
| 2026-01-20 | ALLO | -0.06 | -7.73 | 11.28 |
| 2026-01-21 | ALLO | -0.06 | -7.73 | 11.28 |
| 2026-01-22 | ALLO | -0.06 | -7.73 | 11.28 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.19
Avg. EPS Est. Current Quarter
-0.22
Avg. EPS Est. Next Quarter
-0.21
Insider Transactions
-0.06
Institutional Transactions
-7.73
Beta
0.59
Average Sales Estimate Current Quarter
Average Sales Estimate Next Quarter
Fair Value
Quality Score
9
Growth Score
22
Sentiment Score
35
Actual DrawDown %
95.6
Max Drawdown 5-Year %
-97.6
Target Price
7.38
P/E
Forward P/E
PEG
P/S
P/B
1.22
P/Free Cash Flow
EPS
-0.98
Average EPS Est. Cur. Y
-0.94
EPS Next Y. (Est.)
-0.89
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
Relative Volume
1.95
Return on Equity vs Sector %
-94.5
Return on Equity vs Industry %
-78.6
EPS 1 7Days Diff
EPS 1 30Days Diff
0.09
EBIT Estimation
Allogene Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 226
Allogene Therapeutics, Inc. a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer and autoimmune diseases. It develops, manufactures, and commercializes UCART19, an allogeneic anti-CD19 chimeric antigen receptor (CAR) T cell product candidate for the treatment of patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma. In addition, it provides clinical-stage products, such as ALLO-501, cema-cel, ALLO-316, ALLO-329, ALLO-715, and ALLO-605; DLL3 for the treatment of small cell lung cancer; Claudin 18.2 for the treatment of gastric and pancreatic cancer; and FLT3 for the treatment of acute myeloid leukemia. The company has license and collaboration agreements with Pfizer Inc., Servier, Cellectis S.A., and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
stock quote shares ALLO – Allogene Therapeutics, Inc. Stock Price stock today
news today ALLO – Allogene Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025
marketwatch ALLO – Allogene Therapeutics, Inc. yahoo finance google finance
stock history ALLO – Allogene Therapeutics, Inc. invest stock market
stock prices ALLO premarket after hours
ticker ALLO fair value insiders trading